These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8141139)

  • 1. Long-term oral anticoagulant therapy: update on indications, therapeutic ranges, and monitoring.
    Raj G; Kumar R; McKinney WP
    Am J Med Sci; 1994 Feb; 307(2):128-32. PubMed ID: 8141139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral anticoagulant therapy.
    Raskob GE
    Curr Opin Hematol; 1996 Sep; 3(5):361-4. PubMed ID: 9372102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.
    Palareti G; Leali N; Coccheri S; Poggi M; Manotti C; D'Angelo A; Pengo V; Erba N; Moia M; Ciavarella N; Devoto G; Berrettini M; Musolesi S
    Lancet; 1996 Aug; 348(9025):423-8. PubMed ID: 8709780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of oral anticoagulant treatment in patients with venous thromboembolism.
    Pengo V
    Semin Thromb Hemost; 2006 Nov; 32(8):781-6. PubMed ID: 17171590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.
    Toth PP
    Vasc Health Risk Manag; 2016; 12():23-34. PubMed ID: 26929637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient self-monitoring of oral anticoagulant therapy: potential benefits and implications for clinical practice.
    Douketis JD
    Am J Cardiovasc Drugs; 2001; 1(4):245-51. PubMed ID: 14728024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer anticoagulants in cardiovascular disease: a systematic review of the literature.
    Maan A; Padmanabhan R; Shaikh AY; Mansour M; Ruskin JN; Heist EK
    Cardiol Rev; 2012; 20(5):209-21. PubMed ID: 22370770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation: managing adverse events in patients receiving anticoagulation and perioperative care.
    Hawes EM; Viera AJ
    FP Essent; 2014 Jul; 422():31-9; quiz 40-3. PubMed ID: 25033004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy.
    Goldhaber SZ
    J Thromb Thrombolysis; 2006 Feb; 21(1):51-2. PubMed ID: 16475042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated guidelines on outpatient anticoagulation.
    Wigle P; Hein B; Bloomfield HE; Tubb M; Doherty M
    Am Fam Physician; 2013 Apr; 87(8):556-66. PubMed ID: 23668445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and long-term management of venous thromboembolism.
    Al-Badri A; Spyropoulos AC
    Clin Lab Med; 2014 Sep; 34(3):519-36. PubMed ID: 25168940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic target values in oral anticoagulation--justification of Dutch policy and a warning against the so-called moderate-intensity regimens.
    Loeliger EA
    Ann Hematol; 1992 Feb; 64(2):60-5. PubMed ID: 1554796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological monitoring of treatment with antivitamin K. Value of INR and definition of new therapeutic ranges. A study of 73 patients].
    Gouin I; Horellou MH; Conard J; Samama M
    Arch Mal Coeur Vaiss; 1990 Mar; 83(3):357-61. PubMed ID: 2108630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
    N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coumarin therapy in thrombosis.
    Pineo G; Hull RD
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):201-16, viii. PubMed ID: 12627669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.